Circulating IL-33 level is associated with the progression of lung cancer

被引：53

作者：

Kim, Myung Shin ^{[1
]}

Kim, Eunsom ^{[2
]}

Heo, Jeong-Seok ^{[3
]}

Bae, Da-Jeong ^{[3
]}

Lee, Jong-Uk Wook ^{[3
]}

Lee, Tae-Hyeong ^{[3
]}

Lee, Hyeon Ju ^{[3
]}

Chang, Hun Soo ^{[3
]}

Park, Jong Sook ^{[4
]}

Jang, An Soo ^{[4
]}

Koh, Eun Suk ^{[5
]}

Hwang, Hun Gyu ^{[1
]}

Lim, Guneil ^{[1
]}

Kim, Soohyun ^{[2
]}

Park, Choon-Sik ^{[4
]}

机构：

[1] Soonchunhyang Univ, Gumi Hosp, Dept Internal Med, Div Allergy & Resp Med, Gumi Si, Gyeongsangbuk D, South Korea

[2] Konkuk Univ, Dept Biomed Sci & Technol, Lab Cytokine Immunol, Seoul 05029, South Korea

[3] Soonchunhyang Grad Sch, Dept Interdisciplinary Program Biomed Sci Major, Bucheon 420767, Gyeonggi Do, South Korea

[4] Soonchunhyang Univ, Bucheon Hosp, Dept Internal Med, Div Allergy & Resp Med, Bucheon 420020, Gyeonggi Do, South Korea

[5] Soonchunhyang Univ, Bucheon Hosp, Dept Anat Pathol, Bucheon 420020, Gyeonggi Do, South Korea

来源：

LUNG CANCER | 2015年 / 90卷 / 02期

基金：

新加坡国家研究基金会;

关键词：

Interleukin-33; Lung cancer; Surgery; Chemotherapy; Stage; Plasma; ACQUIRED-IMMUNITY; NK CELLS; T-CELLS; KAPPA-B; CYTOKINE; INNATE; EXPRESSION; CARCINOMA; RESPONSES; ACTS;

D O I：

10.1016/j.lungcan.2015.08.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objectives: Interleukin (IL)-33 protects against infection and inflammation; however, few studies have explored the relevance of IL-33 in lung cancer patients. We evaluated relation of plasma IL-33 levels with development and progression of lung cancer. Materials and Methods: A total of 160 patients with lung cancer and 160 controls with normal lungs were enrolled. Plasma IL-33 levels were measured using a specific sandwich ELISA; these levels were followed-up in 18 patients who underwent surgery and in 14 patients treated with chemotherapy. Malignant lesions and normal lung tissues from 10 cancer patients were subjected to immunohistochemical staining for IL-33. Results: IL-33 levels were significantly lower in cancer patients than normal controls (0.08 vs. 0.38 ng/mL, p = 0.005). Among cancer patients, IL-33 decreased in a stage-dependent manner from 0.76 ng/mL in stage I patients to 0.25 ng/mL in those with stage II, 0.08 ng/mL in those with stage III, and 0.08 ng/mL in those with stage IV (p = 0.002). The levels were higher at stage I (p = 0.041) and markedly lower at stages III and IV than those of controls (p = 0.005 and p = 0.001, respectively). A similar pattern was observed when IL-33 levels were analyzed by T stage; the levels were 0.39 ng/mL at T1/T2 vs. 0.08 ng/mL at T3/T4 (p = 0.001). However, no difference was noted when stage N1 levels were compared with N2 and N3 levels (p = 0.058), or between stage MO and M1 levels (p = 0.147). IL-33 levels gradually decreased after surgical resection of malignant lesions (from 1.075 to 0.756 ng/mL, p = 0.006), but were unchanged after chemotherapy (0.705 vs. 0.829 ng/mL, p = 0.875). On immunohistochemical staining, bronchial epithelial and vascular endothelial cells of normal lung tissues mainly expressed IL-33. Conclusions: Plasma IL-33 levels are associated inversely with progression of lung cancer. The observed decreases may be attributed to lung volume reduction containing bronchial epithelium and vascular endothelium as the sources of IL-33. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

引用

页码：346 / 351

页数：6

共 34 条

[1] Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules [J].